Researches and develops pharmaceutical products. Manufactures intravenous infusion solutions in various formats. Now — the numbers.
This is an established company with proven profits.
An average decline of 6% a year over the last 4 years — the most striking risk in this picture.
The gap is $280.2M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 19.8× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 42% below its peak. The market has trimmed its expectations for the company.
It pays out $0.01 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.40. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 4 years, sales fell about 6% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.